BioScrip Stock Price, News & Analysis (NASDAQ:BIOS)

$2.66 -0.01 (-0.37 %)
(As of 12/13/2017 01:49 PM ET)
Previous Close$2.67
Today's Range$2.61 - $2.73
52-Week Range$0.98 - $3.39
Volume392,000 shs
Average Volume1.70 million shs
Market Capitalization$340.47 million
P/E RatioN/A
Dividend YieldN/A
Beta0.27

About BioScrip (NASDAQ:BIOS)

BioScrip logoBioScrip, Inc. is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment. The Company operates through approximately 70 service locations in over 30 states. The Company offers home infusion services to provide clinical management services and the delivery of prescription medications. The Company provides services in coordination with, and under the direction of, the patient's physician. The Company's multidisciplinary team of clinicians, including pharmacists, nurses, dietitians and respiratory therapists, work with the physician to develop a plan of care suited to the patient's specific needs. Its platform provides service capabilities to deliver clinical management services that offer patients a community-based and home-based care environment.

Receive BIOS News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Hospitals, Clinics & Primary Care Services
Sub-IndustryHealth Care Services
SectorMedical
SymbolNASDAQ:BIOS
CUSIP09069N10
Phone720-697-5200

Debt

Debt-to-Equity Ratio-6.11%
Current Ratio1.91%
Quick Ratio1.60%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$935.59 million
Price / Sales0.36
Cash FlowN/A
Price / CashN/A
Book Value($0.27) per share
Price / Book-9.85

Profitability

Trailing EPS($0.68)
Net Income$-41,500,000.00
Net Margins-8.42%
Return on EquityN/A
Return on Assets-8.01%

Miscellaneous

Employees2,540
Outstanding Shares127,520,000

BioScrip (NASDAQ:BIOS) Frequently Asked Questions

What is BioScrip's stock symbol?

BioScrip trades on the NASDAQ under the ticker symbol "BIOS."

How were BioScrip's earnings last quarter?

BioScrip Inc (NASDAQ:BIOS) announced its quarterly earnings results on Thursday, November, 2nd. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.10) by $0.02. The business had revenue of $198.70 million for the quarter, compared to analyst estimates of $202.91 million. The firm's quarterly revenue was down 11.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.12) EPS. View BioScrip's Earnings History.

When will BioScrip make its next earnings announcement?

BioScrip is scheduled to release their next quarterly earnings announcement on Thursday, March, 1st 2018. View Earnings Estimates for BioScrip.

Where is BioScrip's stock going? Where will BioScrip's stock price be in 2017?

4 Wall Street analysts have issued 12 month price objectives for BioScrip's stock. Their forecasts range from $3.00 to $4.50. On average, they anticipate BioScrip's stock price to reach $3.75 in the next year. View Analyst Ratings for BioScrip.

What are Wall Street analysts saying about BioScrip stock?

Here are some recent quotes from research analysts about BioScrip stock:

  • 1. According to Zacks Investment Research, "BioScrip exited the third quarter on a dismal note, with earnings and revenues missing the Zacks Consensus Estimate. We are encouraged by the company’s recent progress, courtesy of its new multi-faceted CORE plan to improve the financial position. We are also upbeat about the company’s completion of the UnitedHealthcare contract transition and expectations of strong core revenue growth. Accordingly, over the last six months, BioScrip has been trading above the broader industry. On the flip side, a competitive landscape continues to be a major dampener. Also, management’s slashed guidance for 2017 adds to our concerns." (11/7/2017)
  • 2. Jefferies Group LLC analysts commented, "We are incrementally more positive on BIOS following better-than-expected 4Q results. Growth in Core revenues is progressing according to plan & expense initiatives should offset a majority of the headwind from the 21st Century Cures Act. Accelerating EBITDA growth throughout 2017 should provide investors with increasing confidence in BIOS ability to reduce debt leverage to more normalized levels (~6x) by YE17 & put BIOS on a path to >$80MM of EBITDA in 2018." (3/6/2017)

Who are some of BioScrip's key competitors?

Who are BioScrip's key executives?

BioScrip's management team includes the folowing people:

  • Daniel E. Greenleaf, President, Chief Executive Officer, Director (Age 51)
  • Stephen M. Deitsch, Chief Financial Officer, Senior Vice President, Treasurer (Age 45)
  • Harriet Booker, Chief Operating Officer, Senior Vice President (Age 51)
  • Betty Y Jang, Senior Vice President, Chief Compliance Officer (Age 47)
  • Danny Claycomb, Senior Vice President - Revenue Cycle Management
  • Tony Lopez, Vice President, Chief Accounting Officer, Controller (Age 51)
  • Kathryn M. Stalmack, General Counsel
  • Scott J. Davido, Chief Implementation Officer (Age 48)
  • Michael G. Bronfein CPA, Director (Age 60)
  • Steven Neumann, Director

Who owns BioScrip stock?

BioScrip's stock is owned by a number of of retail and institutional investors. Top institutional investors include Gilder Gagnon Howe & Co. LLC (12.36%), VENOR CAPITAL MANAGEMENT LP (10.32%), Gabelli Funds LLC (7.96%), Diamond Hill Capital Management Inc. (2.98%), Dimensional Fund Advisors LP (0.70%) and Gamco Investors INC. ET AL (0.64%). Company insiders that own BioScrip stock include Coliseum Capital Management, L, Daniel E Greenleaf, David W Golding, Jeffrey M Kreger, Michael G Bronfein, R Carter Pate and Stephen Deitsch. View Institutional Ownership Trends for BioScrip.

Who sold BioScrip stock? Who is selling BioScrip stock?

BioScrip's stock was sold by a variety of institutional investors in the last quarter, including Gabelli Funds LLC, Diamond Hill Capital Management Inc., Teton Advisors Inc., Dimensional Fund Advisors LP, Gamco Investors INC. ET AL and California Public Employees Retirement System. Company insiders that have sold BioScrip company stock in the last year include Coliseum Capital Management, L and Michael G Bronfein. View Insider Buying and Selling for BioScrip.

Who bought BioScrip stock? Who is buying BioScrip stock?

BioScrip's stock was acquired by a variety of institutional investors in the last quarter, including Fuller & Thaler Asset Management Inc., Gilder Gagnon Howe & Co. LLC, GSA Capital Partners LLP, Royce & Associates LP, Engineers Gate Manager LP, Skylands Capital LLC, Highbridge Capital Management LLC and Wells Fargo & Company MN. Company insiders that have bought BioScrip stock in the last two years include Coliseum Capital Management, L, Daniel E Greenleaf, David W Golding, Jeffrey M Kreger, R Carter Pate and Stephen Deitsch. View Insider Buying and Selling for BioScrip.

How do I buy BioScrip stock?

Shares of BioScrip can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioScrip's stock price today?

One share of BioScrip stock can currently be purchased for approximately $2.66.

How big of a company is BioScrip?

BioScrip has a market capitalization of $340.47 million and generates $935.59 million in revenue each year. The company earns $-41,500,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis. BioScrip employs 2,540 workers across the globe.

How can I contact BioScrip?

BioScrip's mailing address is 1600 BROADWAY SUITE 950, DENVER CO, 80202. The company can be reached via phone at 720-697-5200 or via email at [email protected]


MarketBeat Community Rating for BioScrip (BIOS)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  165 (Vote Outperform)
Underperform Votes:  110 (Vote Underperform)
Total Votes:  275
MarketBeat's community ratings are surveys of what our community members think about BioScrip and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

BioScrip (NASDAQ:BIOS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $3.75$3.75$3.94$3.25
Price Target Upside: 81.16% upside81.16% upside36.25% upside76.63% upside

BioScrip (NASDAQ:BIOS) Consensus Price Target History

Price Target History for BioScrip (NASDAQ:BIOS)

BioScrip (NASDAQ:BIOS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/3/2017SunTrust BanksReiterated RatingBuy$3.00N/AView Rating Details
8/10/2017Jefferies GroupReiterated RatingBuy$3.00 -> $4.00HighView Rating Details
6/26/2017Barrington ResearchBoost Price TargetOutperform$3.50HighView Rating Details
1/3/2017Lake Street CapitalInitiated CoverageBuy$4.50N/AView Rating Details
3/5/2016StephensReiterated RatingBuyN/AView Rating Details
(Data available from 12/13/2015 forward)

Earnings

BioScrip (NASDAQ:BIOS) Earnings History and Estimates Chart

Earnings by Quarter for BioScrip (NASDAQ:BIOS)

BioScrip (NASDAQ BIOS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/1/2018($0.08)N/AView Earnings Details
11/2/2017Q3 2017($0.10)($0.12)$202.91 million$198.70 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.10)($0.11)$220.05 million$218.11 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.12)($0.16)$230.23 million$217.80 millionViewListenView Earnings Details
3/3/2017Q4 2016($0.08)($0.08)$236.67 million$240.10 millionViewListenView Earnings Details
11/7/2016Q3($0.05)($0.12)$223.26 million$224.50 millionViewListenView Earnings Details
8/8/2016Q216($0.09)($0.08)$229.58 million$232.50 millionViewListenView Earnings Details
5/5/2016Q1($0.12)($0.17)$232.38 million$238.50 millionViewListenView Earnings Details
3/2/2016Q4($0.08)($0.13)$238.30 million$243.75 millionViewListenView Earnings Details
11/4/2015Q315($0.10)($0.19)$229.89 million$247.20 millionViewListenView Earnings Details
8/10/2015Q215($0.11)($0.02)$269.38 million$262.40 millionViewListenView Earnings Details
5/7/2015Q115($0.08)($0.19)$259.60 million$261.70 millionViewListenView Earnings Details
3/2/2015Q414($0.02)($0.72)$259.62 million$253.70 millionViewListenView Earnings Details
11/5/2014Q314$0.02($0.45)$240.08 million$244.00 millionViewListenView Earnings Details
8/6/2014Q214($0.05)($0.10)$233.70 million$247.10 millionViewListenView Earnings Details
5/8/2014Q114($0.04)($0.17)$222.65 million$239.60 millionViewListenView Earnings Details
2/26/2014Q413$0.02$0.02$237.58 million$243.50 millionViewListenView Earnings Details
8/7/2013Q2 2013$0.04$0.13$206.47 million$190.73 millionViewListenView Earnings Details
5/8/2013Q1 2013$0.02$0.04$189.36 million$199.07 millionViewListenView Earnings Details
3/11/2013Q4 2012$0.01$0.04$173.87 million$180.70 millionViewListenView Earnings Details
11/7/2012Q312($0.01)($0.01)$159.86 million$170.36 millionViewN/AView Earnings Details
8/8/2012($0.01)($0.07)ViewN/AView Earnings Details
5/9/2012($0.01)($0.05)ViewN/AView Earnings Details
3/9/2012$0.09$0.12ViewN/AView Earnings Details
11/8/2011$0.09$0.10ViewN/AView Earnings Details
8/8/2011$0.08$0.10ViewN/AView Earnings Details
5/3/2011($0.01)$0.05ViewN/AView Earnings Details
3/11/2011$0.04($1.25)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

BioScrip (NASDAQ:BIOS) Earnings Estimates

2017 EPS Consensus Estimate: ($0.28)
2018 EPS Consensus Estimate: ($0.19)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.14)($0.08)($0.12)
Q2 20172($0.10)($0.06)($0.08)
Q3 20173($0.08)($0.04)($0.06)
Q4 20173($0.04)($0.02)($0.03)
Q1 20182($0.10)($0.06)($0.08)
Q2 20182($0.07)($0.05)($0.06)
Q3 20182($0.06)($0.03)($0.05)
Q4 20182($0.01)$0.00($0.01)
Q1 20191($0.04)($0.04)($0.04)
Q2 20191($0.03)($0.03)($0.03)
Q3 20191($0.02)($0.02)($0.02)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for BioScrip (NASDAQ:BIOS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

BioScrip (NASDAQ BIOS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.80%
Institutional Ownership Percentage: 84.69%
Insider Trades by Quarter for BioScrip (NASDAQ:BIOS)
Institutional Ownership by Quarter for BioScrip (NASDAQ:BIOS)

BioScrip (NASDAQ BIOS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/9/2017Daniel E GreenleafCEOBuy15,000$2.03$30,450.00View SEC Filing  
11/9/2017Stephen DeitschCFOBuy10,000$2.03$20,300.00View SEC Filing  
9/15/2017Michael G BronfeinDirectorSell27,000$2.69$72,630.00View SEC Filing  
9/7/2017Coliseum Capital Management, LDirectorSell2,846,941$2.93$8,341,537.13View SEC Filing  
8/17/2017Coliseum Capital Management, LDirectorSell886,478$3.08$2,730,352.24View SEC Filing  
11/11/2016Jeffrey M KregerCFOBuy10,000$1.32$13,200.00View SEC Filing  
11/10/2016Daniel E GreenleafCEOBuy16,000$1.30$20,800.00View SEC Filing  
11/10/2016R Carter PateDirectorBuy20,000$1.30$26,000.00View SEC Filing  
6/22/2016Coliseum Capital Management, LDirectorBuy4,200,000$2.00$8,400,000.00View SEC Filing  
6/17/2016David W GoldingDirectorBuy12,500$2.48$31,000.00View SEC Filing  
8/24/2015Coliseum Capital Management, LDirectorBuy789,503$1.88$1,484,265.64View SEC Filing  
8/21/2015Coliseum Capital Management, LDirectorBuy632,907$1.81$1,145,561.67View SEC Filing  
8/18/2015David W GoldingDirectorBuy20,000$1.54$30,800.00View SEC Filing  
3/16/2015Richard M SmithCEOBuy5,000$4.27$21,350.00View SEC Filing  
3/12/2015Yon JordenDirectorBuy5,000$3.47$17,350.00View SEC Filing  
6/16/2014Myron Z HolubiakDirectorSell5,000$7.94$39,700.00View SEC Filing  
5/14/2014Yon JordenDirectorBuy5,000$7.21$36,050.00View SEC Filing  
8/30/2013Daniel ColucciVPSell18,500$12.40$229,400.00View SEC Filing  
8/28/2013David HubersDirectorSell11,200$12.23$136,976.00View SEC Filing  
8/28/2013Patricia BoguszVPSell39,687$11.94$473,862.78View SEC Filing  
8/19/2013Kohlberg Management V, LlcInsiderSell6,895,873$13.00$89,646,349.00View SEC Filing  
7/19/2013Myron Z HolubiakDirectorSell31,200$16.34$509,808.00View SEC Filing  
11/13/2012Stuart A SamuelsDirectorSell11,200$9.66$108,192.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

BioScrip (NASDAQ BIOS) News Headlines

Source:
DateHeadline
Analyzing BioScrip (BIOS) and Its PeersAnalyzing BioScrip (BIOS) and Its Peers
www.americanbankingnews.com - December 12 at 5:16 PM
Comparing BioScrip (BIOS) & Its CompetitorsComparing BioScrip (BIOS) & Its Competitors
www.americanbankingnews.com - December 11 at 11:22 PM
ETFs with exposure to BioScrip, Inc. : December 11, 2017ETFs with exposure to BioScrip, Inc. : December 11, 2017
finance.yahoo.com - December 11 at 5:27 PM
Reviewing BioScrip (BIOS) and Its PeersReviewing BioScrip (BIOS) and Its Peers
www.americanbankingnews.com - December 8 at 9:08 PM
Critical Contrast: BioScrip (BIOS) versus Its RivalsCritical Contrast: BioScrip (BIOS) versus Its Rivals
www.americanbankingnews.com - December 8 at 5:14 PM
Comparing AMERIGROUP (AGP) & BioScrip (BIOS)Comparing AMERIGROUP (AGP) & BioScrip (BIOS)
www.americanbankingnews.com - December 7 at 5:50 AM
Financial Comparison: BioScrip (BIOS) & The CompetitionFinancial Comparison: BioScrip (BIOS) & The Competition
www.americanbankingnews.com - December 7 at 1:22 AM
BioScrip (BIOS) & Its Rivals Head to Head AnalysisBioScrip (BIOS) & Its Rivals Head to Head Analysis
www.americanbankingnews.com - December 6 at 9:58 AM
 Analysts Anticipate BioScrip, Inc. (BIOS) Will Post Quarterly Sales of $171.79 Million Analysts Anticipate BioScrip, Inc. (BIOS) Will Post Quarterly Sales of $171.79 Million
www.americanbankingnews.com - December 6 at 5:00 AM
 Brokerages Expect BioScrip, Inc. (BIOS) to Announce -$0.08 Earnings Per Share Brokerages Expect BioScrip, Inc. (BIOS) to Announce -$0.08 Earnings Per Share
www.americanbankingnews.com - December 4 at 5:12 PM
BioScrip, Inc. (BIOS) Receives Consensus Recommendation of "Hold" from AnalystsBioScrip, Inc. (BIOS) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - December 4 at 3:46 AM
Analyzing BioScrip (BIOS) and The CompetitionAnalyzing BioScrip (BIOS) and The Competition
www.americanbankingnews.com - December 1 at 11:38 AM
Critical Contrast: BioScrip (BIOS) vs. The CompetitionCritical Contrast: BioScrip (BIOS) vs. The Competition
www.americanbankingnews.com - December 1 at 3:32 AM
BioScrip (BIOS) Stock Rating Upgraded by ValuEngineBioScrip (BIOS) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - November 30 at 11:02 PM
ETFs with exposure to BioScrip, Inc. : November 30, 2017ETFs with exposure to BioScrip, Inc. : November 30, 2017
finance.yahoo.com - November 30 at 5:11 PM
Pre-market Technical Scan on Healthcare Equities -- Anthem, Cigna, Amedisys, and BioScrip - PR Newswire (press release)Pre-market Technical Scan on Healthcare Equities -- Anthem, Cigna, Amedisys, and BioScrip - PR Newswire (press release)
www.prnewswire.com - November 30 at 10:04 AM
BioScrip to Host Meetings at the Mizuho Investor Conference - GlobeNewswire (press release)BioScrip to Host Meetings at the Mizuho Investor Conference - GlobeNewswire (press release)
globenewswire.com - November 30 at 10:04 AM
BioScrip to Host Meetings at the Mizuho Investor ConferenceBioScrip to Host Meetings at the Mizuho Investor Conference
finance.yahoo.com - November 30 at 10:04 AM
Analyzing BioScrip (BIOS) & Its PeersAnalyzing BioScrip (BIOS) & Its Peers
www.americanbankingnews.com - November 30 at 9:30 AM
BioScrip Announces Additions to Senior Leadership Team - GlobeNewswire (press release)BioScrip Announces Additions to Senior Leadership Team - GlobeNewswire (press release)
globenewswire.com - November 29 at 5:34 PM
BioScrip (BIOS) Names Harriet Booker as COOBioScrip (BIOS) Names Harriet Booker as COO
www.streetinsider.com - November 29 at 9:44 AM
Head to Head Analysis: BioScrip (BIOS) & Its RivalsHead to Head Analysis: BioScrip (BIOS) & Its Rivals
www.americanbankingnews.com - November 29 at 1:14 AM
Reviewing BioScrip (BIOS) & Its CompetitorsReviewing BioScrip (BIOS) & Its Competitors
www.americanbankingnews.com - November 28 at 11:24 PM
BioScrip Announces Additions to Senior Leadership TeamBioScrip Announces Additions to Senior Leadership Team
finance.yahoo.com - November 28 at 5:13 PM
Head to Head Contrast: BioScrip (BIOS) and Its PeersHead to Head Contrast: BioScrip (BIOS) and Its Peers
www.americanbankingnews.com - November 25 at 9:26 AM
Comparing BioScrip (BIOS) & The CompetitionComparing BioScrip (BIOS) & The Competition
www.americanbankingnews.com - November 25 at 5:10 AM
Head-To-Head Survey: BioScrip (BIOS) versus Its CompetitorsHead-To-Head Survey: BioScrip (BIOS) versus Its Competitors
www.americanbankingnews.com - November 24 at 9:34 AM
Critical Review: BioScrip (BIOS) and Its RivalsCritical Review: BioScrip (BIOS) and Its Rivals
www.americanbankingnews.com - November 23 at 1:28 PM
Financial Contrast: BioScrip (BIOS) and The CompetitionFinancial Contrast: BioScrip (BIOS) and The Competition
www.americanbankingnews.com - November 23 at 5:24 AM
BioScrip, Inc. breached its 50 day moving average in a Bullish Manner : BIOS-US : November 22, 2017BioScrip, Inc. breached its 50 day moving average in a Bullish Manner : BIOS-US : November 22, 2017
finance.yahoo.com - November 22 at 5:15 PM
Financial Comparison: BioScrip (BIOS) versus The CompetitionFinancial Comparison: BioScrip (BIOS) versus The Competition
www.americanbankingnews.com - November 21 at 5:22 PM
Comparing BioScrip (BIOS) & Its PeersComparing BioScrip (BIOS) & Its Peers
www.americanbankingnews.com - November 21 at 1:34 PM
Head to Head Analysis: BioScrip (BIOS) and Its PeersHead to Head Analysis: BioScrip (BIOS) and Its Peers
www.americanbankingnews.com - November 21 at 7:42 AM
BioScrip (BIOS) vs. The Competition Financial ContrastBioScrip (BIOS) vs. The Competition Financial Contrast
www.americanbankingnews.com - November 21 at 5:12 AM
ETFs with exposure to BioScrip, Inc. : November 20, 2017ETFs with exposure to BioScrip, Inc. : November 20, 2017
finance.yahoo.com - November 20 at 3:23 PM
Head to Head Survey: BioScrip (BIOS) & Its CompetitorsHead to Head Survey: BioScrip (BIOS) & Its Competitors
www.americanbankingnews.com - November 20 at 3:20 PM
Financial Analysis: BioScrip (BIOS) versus The CompetitionFinancial Analysis: BioScrip (BIOS) versus The Competition
www.americanbankingnews.com - November 19 at 7:14 PM
$177.19 Million in Sales Expected for BioScrip, Inc. (BIOS) This Quarter$177.19 Million in Sales Expected for BioScrip, Inc. (BIOS) This Quarter
www.americanbankingnews.com - November 18 at 9:42 AM
What does BioScrip Inc’s (BIOS) Balance Sheet Tell Us Abouts Its Future?What does BioScrip Inc’s (BIOS) Balance Sheet Tell Us Abouts Its Future?
finance.yahoo.com - November 17 at 2:46 PM
BioScrip to Present at Bank of America Merrill Lynch 2017 Leveraged Finance ConferenceBioScrip to Present at Bank of America Merrill Lynch 2017 Leveraged Finance Conference
finance.yahoo.com - November 16 at 9:33 AM
BIOS: Insiders Vs. ShortsBIOS: Insiders Vs. Shorts
www.thestreet.com - November 14 at 5:03 PM
Insider Buying: BioScrip, Inc. (BIOS) CFO Buys 10,000 Shares of StockInsider Buying: BioScrip, Inc. (BIOS) CFO Buys 10,000 Shares of Stock
www.americanbankingnews.com - November 13 at 8:21 PM
Daniel E. Greenleaf Acquires 15,000 Shares of BioScrip, Inc. (BIOS) StockDaniel E. Greenleaf Acquires 15,000 Shares of BioScrip, Inc. (BIOS) Stock
www.americanbankingnews.com - November 13 at 6:54 PM
BioScrip to Host Meetings at the 8th Annual Craig-Hallum Alpha Select Conference - GlobeNewswire (press release)BioScrip to Host Meetings at the 8th Annual Craig-Hallum Alpha Select Conference - GlobeNewswire (press release)
globenewswire.com - November 9 at 5:41 PM
BioScrip to Host Meetings at the 8th Annual Craig-Hallum Alpha Select ConferenceBioScrip to Host Meetings at the 8th Annual Craig-Hallum Alpha Select Conference
finance.yahoo.com - November 9 at 5:41 PM
ETFs with exposure to BioScrip, Inc. : November 9, 2017ETFs with exposure to BioScrip, Inc. : November 9, 2017
finance.yahoo.com - November 9 at 5:41 PM
BioScrip, Inc. (BIOS) Given Consensus Rating of "Hold" by BrokeragesBioScrip, Inc. (BIOS) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - November 9 at 3:38 AM
BioScrip, Inc. Forecasted to Post Q4 2017 Earnings of ($0.04) Per Share (BIOS)BioScrip, Inc. Forecasted to Post Q4 2017 Earnings of ($0.04) Per Share (BIOS)
www.americanbankingnews.com - November 8 at 4:34 PM
BioScrip, Inc. (BIOS) Downgraded by Zacks Investment ResearchBioScrip, Inc. (BIOS) Downgraded by Zacks Investment Research
www.americanbankingnews.com - November 7 at 8:26 PM
BioScrip, Inc. :BIOS-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017BioScrip, Inc. :BIOS-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017
finance.yahoo.com - November 7 at 7:22 PM

SEC Filings

BioScrip (NASDAQ:BIOS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

BioScrip (NASDAQ:BIOS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

BioScrip (NASDAQ BIOS) Stock Chart for Wednesday, December, 13, 2017

Loading chart…

This page was last updated on 12/13/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.